Breast

PROJECT_NO PI_NAME PROJECT_TITLE CTRI_NO STATUS DEPARTMENT DMG
321 Dr. Rajesh Dikshit Pattern of care and survival studies Breast cancer Active Enrollment ongoing Bio Statistics Breast
349 Dr. Ashwini Budrukkar A randomized trial of concurrent versus sequential Tamoxifen with radiotherapy to assess the extent of pulmonary fibrosis and disease related control and survival in breast cancer patients NCT00896155 Accrual completed and follow-up ongoing Radiation Oncology Breast
656 Dr. Rajendra Badwe A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel versus Weekly Paclitaxel Plus Weekly Carboplatin in Women with Triple Negative Breast Cancer CTRI/2012/07/002802 Accrual completed and follow-up ongoing Surgical Oncology Breast
735 Dr. Shalaka Joshi Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer REF/2014/03/006566 Accrual completed and follow-up ongoing Surgical Oncology Breast
902 Dr. Rajendra Badwe Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer CTRI/2014/11/005228 Accrual completed and follow-up ongoing Surgical Oncology Breast
982 Dr. Rajendra Badwe A Phase III Double Blind Randomized Placebo Controlled study of Trastuzumab as Short Duration Preoperative Therapy in patients with HER2-neu Positive Operable Breast Cancer CTRI/2013/12/004263 Active Enrollment ongoing Surgical Oncology Breast
1074 Dr. Rajendra Badwe A Randomized controlled study to evaluate the role of hydroxy-progesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer CTRI/2015/11/006381 Data Analysis ongoing Surgical Oncology Breast
1216 Dr. Sudeep Gupta Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India CTRI/2014/09/004972 Analysis Ongoing Medical Oncology Breast
1348 Dr. Shalaka Joshi To assess the cosmetic outcome in patients undergoing breast conservation surgery (BCS) with or without deep suture approximation of the primary surgical cavity REF/2016/12/012792 Accrual completed and follow-up ongoing Surgical Oncology Breast
1442 Dr. Sabita Jiwnani Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer Data Analysis ongoing Surgical Oncology Breast
1602 Dr. Tabassum Wadasadawala Post-Mastectomy Radiation Therapy in High Risk, Node Negative women with Early Breast Cancer (PMRT-NNBC) CTRI/2016/12/007532 Active enrollment ongoing Radiation Oncology Breast
1607 Dr. Venkatesh Rangarajan NIS expression detection in metastatic breast cancer with 131I NaI Analysis Ongoing Nuclear Medicine Breast
1633 Dr. Rajendra Badwe Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tumour tissues of cancer patients: a prospective in-vivo study CTRI/2017/11/010566 Data Analysis ongoing Surgical Oncology Breast
1683 Dr. Tabassum Wadasadawala Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Toxicity and Patient Reported Outcome Measures. CTRI/2017/01/007745 Accrual completed and intervention ongoing Radiation Oncology Breast
1722 Dr. Sushmita Rath Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes.” CTRI/2017/02/007907 Active Enrollment ongoing Medical Oncology Breast
1784 Dr. Rajiv Sarin A prospective COhort study of breast cancer patients with New bone metastases to estimate QUality of life, health Economics &Risk of skeletal complications (CONQUER) CTRI/2018/03/012317 Active Enrollment ongoing Radiation Oncology Breast
1795 Dr. Sushmita Rath Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco regionally Recurrent or Metastatic Breast Cancer CTRI/2017/01/007695 Active accrual and intervention ongoing Medical Oncology Breast
1912 Dr. Bhavika Kothari A randomized controlled trial to evaluate the safety of breast conserving surgery post neo-adjuvant therapy locally advanced breast cancer. CTRI/2018/05/014158 Active Enrollment ongoing Surgical Oncology Breast
1965 Dr. Sudeep Gupta Pilot study to evaluate the biodistribution & dosimetry of 177Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile CTRI/2018/09/015755 Active Enrollment ongoing Medical Oncology Breast
1972 Dr. Shalaka Joshi CONcurrent versus SEQuential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQuenCE) CTRI/2018/09/015643 Active Enrollment ongoing Surgical Oncology Breast
2024 Dr. Sudeep Gupta Protocol No. - I3Y-MC-JPCF : A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE) CTRI/2017/10/010017 Accrual completed and follow-up ongoing Medical Oncology Breast
3058 Ms. Shabina Siddique Study to assess obesity as defined by Waist Hip Ratio (WHR) and Body Mass Index in women with recently diagnosed breast cancer. REF/2019/06/026368 Data Analysis ongoing Surgical Oncology Breast
3112 Dr. Sudeep Gupta Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. CTRI/2018/06/014390 Accrual completed and follow-up ongoing Medical Oncology Breast
3170 Dr. Rima Pathak A study to evaluate the incidence and factors that predict the incidence of brain metastasis in patients with Her2 neu positive and Triple Negative Breast Cancer Case review/sample review ongoing (audit studies) Radiation Oncology Breast
3175 Dr. Tanuja Shet Androgen blockade - Is this the missing link between mucinous micro-papillary carcinoma and micro-papillary carcinoma of breast. Active Enrollment ongoing Pathology Breast
3177 Dr. Rajiv Sarin A Prospective Randomised trial to assess the clinical utility of TMH Mini Quality of Life (TMQ) questionnaire CTRI/2019/12/022442 Data Analysis ongoing Radiation Oncology Breast
3198 Dr. Anbarasan S. Retrospective study of demographics, pattern of care and outcome of TNBC patients from a tertiary care cancer centre In India. Active enrollment ongoing Medical Oncology Breast
3210 Dr. Sheela Sawant Prevalence of cardiovascular diseases in long term Breast Cancer survivors Active Enrollment ongoing General Medicine Breast
3228 Dr. Omshree Shetty Establishing an in house, cost effective, TMH Predict gene panel for Prognosis and Prediction in Breast Cancer Patients subjected to adjuvant therapy. Data Analysis ongoing Pathology Breast
3302 Dr. Rajesh Dikshit Development of breast cancer risk prediction model using lifestyle factors and polygenic risk score in Indian population. CTRI/2019/10/021652 Active Enrollment ongoing Centre For Cancer Epidemiology Breast
3303 Dr. Rima Pathak Can knowledge based planning improve the efficiency and consistency of spine stereotactic body radiation therapy? Case review/sample review ongoing (audit studies) Radiation Oncology Breast
3304 Dr. Rima Pathak Can knowledge based planning improve in efficiency and consistency of radiation therapy treatment planning in breast cancer patients? Active Enrollment ongoing Radiation Oncology Breast
3367 Dr. Shalaka Joshi Role of toll-like receptors and TLR agonists in modulating response to chemotherapy in TNBC patients CTRI/2020/03/023958 Active Enrollment ongoing Surgical Oncology Breast
3399 Dr. Vinay Shankhdhar A prospective pilot study to evaluate the success of LYMPHA (Lymphatic Microsurgical Preventive Healing Approach) in women undergoing Axillary dissection for breast cancer CTRI/2020/03/024383 Data Analysis ongoing Surgical Oncology Breast
3407 Dr. Tabassum Wadasadawala Impact of Tumor Bed Boost Technique on Toxicity and Aesthetic Outcomes after Breast Conservation Therapy: A Prospective Longitudinal Study CTRI/2020/01/022871 Accrual completed and follow-up ongoing Radiation Oncology Breast
3428 Dr. Bhavika Kothari A randomized controlled trial to Assess the incidence of lymphedema in women with breast cancer undergoing Sentinel lymph node biopsy or Low axillary sampling. (AiSLe) CTRI/2020/04/024460 Active enrollment ongoing Surgical Oncology Breast
3437 Dr. Omshree Shetty Epithelial-mesenchymal transition (EMT) and Breast Cancer Stemness: Defining the role of OVOL and ACTN4 in cross talk Active Enrollment ongoing Pathology Breast
3583 Dr. Rajiv Sarin Impact of COVID-19 pandemic on Breast Cancer management in a Tertiary Cancer Care Centre: A Case Control Study CTRI/2020/11/028969 Accrual completed and follow-up ongoing Radiation Oncology Breast
3650 Dr. Anbarasan S. Randomized multi-centric trial of Oral Metronomic Maintenance Therapy (OMMT) vs Capecitabine (Cape) maintenance in newly diagnosed, locally advanced and/or node positive, non-metastatic triple negative breast cancer (TNBC) patients after the completion of standard therapy along with an exploratory study to assess if circulating tumor DNA (ctDNA) and/or circulating tumor cells (CTCs) can be used as a biomarker to predict the probability of recurrence CTRI/2022/12/047995 Not started/Not initiated Medical Oncology Breast
3675 Dr. Prabhat Bhargava Retrospective and prospective analysis of microinvasive breast cancer: clinicopathological features, treatment and outcome CTRI/2021/07/034916 Active accrual and intervention ongoing Medical Oncology Breast
3708 Dr. Sudeep Gupta Protocol No. - D967JC00001 : A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07) CTRI/2021/03/031928 Accrual completed and intervention ongoing Medical Oncology Breast
3715 Dr. Tabassum Wadasadawala PROspecTive Study on the use of gEriatriC assessment Tools for validation of 1-year mortality in breast cancer patients 65 years and older (PROTECT)_x000D_\n CTRI/2021/07/034792 Accrual completed and intervention ongoing Radiation Oncology Breast
3716 Dr. Prabhat Bhargava Avoiding prophylactic growth factors during paclitaxel phase of dose dense adjuvant chemotherapy in breast cancer CTRI/2022/03/041308 Active Enrollment ongoing Medical Oncology Breast
3734 Dr. Tabassum Wadasadawala Assessment of the Breast Cosmesis using Deep neural networks: an exploratory study (ABCD) NCT05450016 Active Enrollment ongoing Radiation Oncology Breast
3740 Dr. Shalaka Joshi Pilot study for measurement of intra-tumoral interstitial fluid pressure in various cancers CTRI/2021/08/035470 Active Enrollment ongoing Surgical Oncology Breast
3784 Dr. Gauravi Mishra Acceptability, Feasibility and Validity of Clinical Breast Examination by Medical Tactile Examiners as Community Based Outreach Program in Different Locations of India. CTRI registration is in proces Not started/Not initiated Preventive Oncology Breast
3799 Dr. Rima Pathak Impact of on-demand training & audio-visual aids to improve referral rates for genetic counselling and/ testing at a tertiary cancer centre (Mainstreaming Study) CTRI/2022/05/042558 Active Enrollment ongoing Radiation Oncology Breast
3809 Dr. Shalaka Joshi An open label, phase 3 randomized trial to evaluate the role of axillary conservation surgery in breast cancer patients post-neoadjuvant chemotherapy. Short title- Post-chemotherapy Axillary Conservation Surgery (PACS) CTRI/2022/07/044461 Active accrual and intervention ongoing Surgical Oncology Breast
3852 Dr. Sudeep Gupta Protocol No. - WO42633 : Protocol No. - WO42633 : A Phase III, randomized, double-blind,placebo-controlled clinical trial toevaluate the efficacy and safety ofadjuvant atezolizumab or placebo and trastuzumab emtansine forher2-positive breast cancer at high riskof recurrence following preoperativetherapy (ASTEFANIA STUDY)._x000D_\n_x000D_\n CTRI/2021/08/035911 Accrual completed and intervention ongoing Medical Oncology Breast
3877 Dr. Sudeep Gupta Protocol No. - GO42784 : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer CTRI/2022/01/039625 Accrual completed and intervention ongoing Medical Oncology Breast
3888 Dr. Rajiv Sarin Developing a 3D-printed Humanoid Phantom for Breast Cancer Radiotherapy Dosimetry and Quality Assurance Approved Radiation Oncology Breast
3894 Dr. Revathy Krishnamurthy Pilot testing of the Bangla translation of the Tata Memorial Centre Mini Quality of Life Questionnaire (TMQ - Bangla) developed for use in routine oncology practice in India CTRI/2022/02/040246 Active Enrollment ongoing Radiation Oncology Breast
3915 Dr. Sudeep Gupta ICGA: Indian Cancer Genome ATLAS CTRI/2022/09/045570 Active Enrollment ongoing Medical Oncology Breast
3927 Dr. Sudeep Gupta Identifying potentially metastatic cells in primary tissue by identifying specific proteins associated with these phenotypes using an antibody library based screening of TNBC. CTRI/2022/10/046300 Active Enrollment ongoing Medical Oncology Breast
3970 Dr. Anbarasan S. A Pilot Launch of the Oncoshot platform (an online platform for Oncology Clinical Trial matching & other treatment related services) for Cancer Patients, Cancer Hospitals, Oncologists, Pharmaceutical companies & CROs, in the Indian oncology landscape. Not started/Not initiated Medical Oncology Breast
3996 Dr. Ayushi Sahay Concordance of Biomarker Status in Invasive Breast Carcinoma on Re-evaluation- A Retrospective Audit Publication activities ongoing Pathology Breast
4008 Dr. Prabhat Bhargava Protocol No. - CBYL719CIN01 : CBYL719CIN01 ALPelisib INdia Safety STudy (ALPINIST): A Phase IV, prospective, multicenter, open-label, non-comparative, interventional study to assess the safety of alpelisib plus fulvestrant, in men and post-menopausal women with HR- positive, HER2-negative, advanced or metastatic Breast Cancer (ABC or MBC) with a PIK3CA mutation, whose disease has progressed on or after endocrine based treatment. CTRI/2022/04/042205 Data Analysis ongoing Medical Oncology Breast
4054 Dr. Anuradha Daptardar To evaluate the effectiveness of hybrid bandages (Thonic fast and go) in the management of Lymphedema (HY- LYMPH study) CTRI/2023/03/050290 Active Enrollment ongoing Physiotherapy Breast
4055 Dr. Sangeeta Desai Validation of quantitative image analysis (QIA) tools for tissue biomarkers in breast cancer Approved Pathology Breast
4069 Dr. Rajiv Sarin Clinico-radiological presentation, diagnostic dilemmas, management, and clinical outcomes in breast cancer patients with juxta-regional nodal metastasis Accrual completed and follow-up ongoing Radiation Oncology Breast
4071 Dr. Palak Popat Morphological Signature Of Brain Metastases As A Surrogate marker Of Molecular Profile Of Primary Breast Cancer And To Assess Its Feasibility As A Predictive Marker For Prognosis Of Patients With Neuroparenchymal Metastases From Breast Cancer._x000D_\n Approved Radio-diagnosis Breast
4131 Dr. Tabassum Wadasadawala Phase III randomized controlled trial of sequential chemotherapy and radiotherapy versus concurrent chemoradiotherapy in adjuvant treatment of breast cancer CTRI/2023/06/054280 Active accrual and intervention ongoing Radiation Oncology Breast
4144 Dr. Sudeep Gupta WO43571 A Phase III, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo After Induction Therapy With PHESGO + Taxane In Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced Or Metastatic Breast Cancer CTRI/2023/08/056489 Accrual completed and intervention ongoing Medical Oncology Breast
4178 Dr. Sudeep Gupta J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence. CTRI/2023/05/052375 Accrual completed and intervention ongoing Medical Oncology Breast
4182 Dr. Sudeep Gupta C4891001 A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2). CTRI/2023/05/052598 Accrual completed and follow-up ongoing Medical Oncology Breast
4183 Dr. Purvi Haria Role of Shear wave elastography in assessment of response to neoadjuvant chemotherapy (NACT) in breast cancer patients. CTRI/2024/03/063796 Active accrual and intervention ongoing Radio-diagnosis Breast
4222 Dr. Rajendra Badwe PRe-operative ChemoTherapy versus Surgery first with peri-operative interventions in Early triple negative and HER2 enriched breast - an open label, phase 3, randomized controlled trial (PRaCTiSE) CTRI/2024/02/063118 Active enrollment ongoing Surgical Oncology Breast
4226 Dr. Tabassum Wadasadawala Protocol No. - CCR5119 : Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer CTRI/2022/02/040331 Active accrual and intervention ongoing Radiation Oncology Breast
4232 Dr. Tabassum Wadasadawala Burden of financial toxicity in breast cancer patients treated with curative intent: a multinational study from low-middle income countries (FIT study) CTRI/2024/01/062071 Active Enrollment ongoing Radiation Oncology Breast
4243 Dr. Omshree Shetty Tumor Microbiome in Triple Negative Breast Cancers in India Not started/Not initiated Pathology Breast
4248 Dr. Sudeep Gupta RP6530-2301 - A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients with Metastatic Triple Negative Breast Cancer (TNBC) CTRI/2024/01/061635 Active Enrollment ongoing Medical Oncology Breast
4249 Dr. Palak Popat Role of shear wave elastography as a part of Multiparametric ultrasonography in triaging breast lesions for need of biopsy. Active Enrollment ongoing Radio-diagnosis Breast
4254 Dr. Prarthna Shah Addressing diagnostic modalities for identifying HER2 low and ultra-low classes in breast cancer. Active Enrollment ongoing Pathology Breast
4255 Dr. Ayushi Sahay Evaluation of Osteopontin (OPN) Variants in Premalignant Breast Lesions Active Enrollment ongoing Pathology Breast
4273 Dr. Sudeep Gupta Impact of HER2 Low on demographic profile and survival outcomes of Hormone positive breast cancer (HER- IMPACT) CTRI/2024/01/061482 Data Analysis ongoing Medical Oncology Breast
4300 Dr. Sudeep Gupta Evaluation of DSC-3 expression in triple negative breast cancer (TNBC) CTRI/2024/04/064982 Active Enrollment ongoing Medical Oncology Breast
4301 Dr. Sudeep Gupta Real life evidence of Tab Ribociclib for Safety and Efficacy in a tertiary care center( RERISE study). CTRI/2024/01/061744 Case review/sample review ongoing (audit studies) Medical Oncology Breast
4302 Dr. Prabhat Bhargava A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (CAMBRIA-1). CTRI/2024/09/074115 Ongoing Medical Oncology Breast
4338 Dr. Shalaka Joshi Surgical Cosmesis And patient reported outcome measures in patients who have undergone tRansposition flap reconstruction after BCS (SCAR) CTRI/2024/05/066667 Active enrollment ongoing Surgical Oncology Breast
4348 Dr. Tabassum Wadasadawala A RETROSPECTIVE AUDIT OF PATTERNS OF BREAST CANCER RECURRENCE IN LOW-RISK POST MENOPAUSAL WOMEN Case review/sample review ongoing (audit studies) Radiation Oncology Breast
4350 Dr. Sohan Solanki Comparison of effect of Amisulpride and Dexamethasone with Ondansetron and Dexamethasone for postoperative nausea and vomiting after post-chemotherapy breast cancer surgeries: A Randomised Active Controlled Double Blind Study CTRI/2024/04/066189 Active Enrollment ongoing Anaesthesia Breast
4364 Dr. Shalaka Joshi A prospective analysis of postoperative surgical site infection and factors affecting it, including the preoperative HbA1C and fasting blood glucose level, in patients undergoing elective breast oncological surgery. CTRI/2024/06/068383 Data Analysis ongoing Surgical Oncology Breast
4375 Dr. Vikram Gota Study of association between prakriti and outcomes of early and locally advanced breast cancer. CTRI/2025/02/079984 Approved Clinical Pharmacology Breast
4389 Dr. Sushmita Rath A phase II double-arm study of the switch of Endocrine therapy with the change of CDK4/6 inhibitor vs. switch of endocrine therapy alone as second-line and beyond in ER-positive breast cancer patients (SECURE study). CTRI/2024/06/068274 Active Enrollment ongoing Medical Oncology Breast
4409 Dr. Sudeep Gupta BIO-PERTUZ-301 A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® along with Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer. CTRI/2024/02/063261 Active Enrollment ongoing Medical Oncology Breast
4420 Dr. Revathy Krishnamurthy Partial breast re-irradiation using ultra hypofractionation (PRESERVE): Phase 2 multi-institutional study Approved Radiation Oncology Breast
4466 Dr. Palak Popat Automated Breast Ultrasound- Future in breast imaging Not applicable Data Analysis ongoing Radio-diagnosis Breast
4473 Dr. Ayushi Sahay Histopathological Spectrum of Male Breast Cancer: A Retrospective Audit Active Enrollment ongoing Pathology Breast
4475 Dr. Sudeep Gupta C4391022 AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS ATLEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY (FOURLIGHT-1). CTRI/2024/07/069956 Accrual completed and intervention ongoing Medical Oncology Breast
4487 Dr. Palak Popat A PRospective evaluation of impact of additional Imaging modalities in Surgical Management and outcome in Treatment naive breast Cancer patients_x000D_\n_x000D_\nPRiISM Approved Radio-diagnosis Breast
4494 Dr. Rajiv Sarin Audit of Incidence and factors predicting symptomatic radiation necrosis in breast cancer patients treated using Stereotactic Radiosurgery for brain metastasis (SRS-RN STUDY) Approved Radiation Oncology Breast
4538 Dr. Tabassum Wadasadawala Young Women with Breast Cancer: Assessing the unmet needs longitudinally CTRI/2024/11/076743 Active Enrollment ongoing Radiation Oncology Breast
4546 Dr. Anbarasan S. D9673R00037 A Multicenter, Retrospective, Noninterventional Study to Determine the Prevalence of HER2-low, Clinical Characteristics, Treatment Patterns, and Associated Outcomes in Patients Previously Identified With HER2 negative Locally-advanced or Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy. (iRetroBC-HER2L Study). CTRI/2024/03/063553 Approved Medical Oncology Breast
4562 Dr. George John Randomized, double-blind, placebo-controlled study of oral duloxetine in prevention of acute pain syndrome in patients receiving paclitaxel _x000D_\n_x000D_\n CTRI/2024/10/075636 Accrual completed and intervention ongoing Medical Oncology Breast
4567 Dr. Sudeep Gupta MK-2870-010 An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer. CTRI/2024/11/076326 Approved Medical Oncology Breast
4568 Dr. Sushmita Rath Investigate the Role of Tumor Microbiome on Metastatic Triple-Negative Breast Cancer Progression CTRI/2025/08/092895 Approved Medical Oncology Breast
4577 Dr. Sudeep Gupta A case series to report CDK4/6 induced Vitiligo. CTRI/2025/01/079700 Study Initiated and Recruitment Started Medical Oncology Breast
4628 Dr. Sudeep Gupta D9673L00012 A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN. CTRI/2024/07/070945 Approved Medical Oncology Breast
4637 Dr. Shalaka Joshi patient reported outcome measures in breast cancer surgery (TROUSSEAU) CTRI/2025/04/103117 Approved Surgical Oncology Breast
4639 Dr. Tabassum Wadasadawala Mammography based Assessment of Radiological incidence of fat necrosis & Volumetric EvoLution of Breast after Breast Conservation Therapy and Reconstruction (MARVEL) Approved Radiation Oncology Breast
4647 Dr. Sudeep Gupta C4391024 An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study Of PF-07220060 Plus Letrozole Compared To CDK4/6 Inhibitor Plus Letrozole In Participants Over 18 Years Of Age With Hormone Receptor (HR)-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment For Advanced/Metastatic Disease (Fourlight-3). CTRI/2025/04/084336 Approved Medical Oncology Breast
4686 Dr. Sneha Shah Pilot study to evaluate the role of FAPI in lobular variant of breast cancer. Approved Nuclear Medicine Breast
4746 Dr. Shalaka Joshi Validation of dual tracer Sentinel Lymph node biopsy in patients with non-metastatic in-breast tumour recurrence undergoing Re-surgery and study of lymphatic drainage pathways (SLR study) Approved Surgical Oncology Breast
4751 Dr. Tabassum Wadasadawala A pilot study of assessing surgical morbidity of preoperative radiotherapy in women undergoing whole breast reconstruction (SUPER-RT) CTRI/2025/07/090444 Approved Radiation Oncology Breast
4814 Dr. Prabhat Bhargava A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER) CTRI/2025/08/092444 Ongoing Medical Oncology Breast
4821 Dr. Anuradha Mehta A placebo-controlled, randomised phase III trial comparing capecitabine with megestrol acetate or capecitabine with placebo in hormone receptor-positive and HER2-negative metastatic breast cancer (CAMEO STUDY)_x000D_\n_x000D_\n Approved Medical Oncology Breast
4858 Dr. Tanuja Shet Molecular Profiling of Cellular Breast Fibroepithelial Lesions in children and young adults Approved Pathology Breast
4929 Ms. Mamta Gurav Establishing a Molecular and Microenvironmental Basis of Reversed cell Polarity in Breast Cancer Approved Pathology Breast
4935 Dr. C. S. Pramesh Developing cost accounting framework for Tata Memorial Hospital- A pilot study on costing of breast cancer care Approved Surgical Oncology Breast
4977 Dr. Sudeep Gupta Deep Learning on Histopathological Images for Risk Stratification in Indian Breast Cancer Patients. Approved Medical Oncology Breast
5012 Dr. Sneha Shah Retrospective evaluation of impact of Ga 68 FAPI PETCT in lobular variant of breast cancer. Approved Nuclear Medicine Breast